U.S. Food Stock News

Why Box Is On Investors’ Radar Today Box (BOX) is drawing attention after a period of weaker share performance, with the stock showing negative returns over the past month, past 3 months, and year, prompting investors to reassess its current valuation. See our latest analysis for Box. Box’s recent 1 day share price return of a 2.71% decline and 7 day share price return of a 12.99% decline come on top of weaker year to date share price performance. The 5 year total shareholder return of 44.74%...

Earlier this month, JPMorgan upgraded Calix to "Overweight," highlighting a healthier spending backdrop for broadband providers and the company’s exposure to US federal broadband deployment programs aimed at unserved and underserved areas. JPMorgan also pointed to Calix’s upcoming fourth-quarter earnings release and investor day as potential turning points that could further clarify how it may benefit from broadband stimulus funding. Now, we'll examine how JPMorgan's emphasis on Calix's...

What Sila Realty Trust’s latest acquisition could mean for investors Sila Realty Trust (SILA) has agreed to acquire a US$43.1 million inpatient rehabilitation facility in Oklahoma City, a 58 bed property that is fully leased under a long term absolute net lease. The Nobis OKC Facility, recently expanded by 18 beds and about 9,100 square feet to roughly 53,100 square feet, fits the company’s focus on healthcare real estate and may interest investors watching income oriented REITs. See our...

T. Rowe Price recently launched Income Solver through its fintech subsidiary Retiree Inc., offering advisors software to design personalized, tax-aware retirement withdrawal strategies that coordinate investment assets, Social Security, Medicare premiums, and other income sources. The tool is built on proprietary research that the company says can significantly extend retirement income while reducing manual planning work for advisors, underscoring T. Rowe Price’s focus on higher-value...

Pomerantz LLP is investigating Cogent Communications Holdings over potential securities law violations after the company previously reported a nearly 6% year-over-year service revenue decline and a 98% dividend reduction in November 2025. This combination of legal scrutiny and sharp cuts to shareholder payouts highlights growing concerns about Cogent’s financial flexibility and business resilience. We’ll now examine how the securities investigation and sharp dividend reduction may affect...

Earlier this month, Chinese authorities instructed domestic firms to stop using certain foreign cybersecurity software, including Broadcom-owned VMware products, citing national security concerns and adding fresh pressure to U.S. tech suppliers in the country. At the same time, Broadcom moved ahead with its AI-focused Wi‑Fi 8 platform and a US$4.50 billion senior notes issuance, underscoring how regulatory headwinds in China are emerging just as the company deepens its push into AI...

Wondering whether QXO at around US$23.81 is offering fair value or an opportunity? This article walks through what the current price actually reflects. The stock has been volatile recently, with a 4.8% decline over the last 7 days, a 14.5% gain over 30 days, a 20.7% return year to date, and a 70.2% return over the past year. The 3 year and 5 year returns sit at 11.6% and a 13.6% decline respectively. Recent coverage has focused on QXO as a name that has drawn attention following its share...

Organon’s Nilemdo deal and recent share move Organon (OGN) has signed an agreement with Daiichi Sankyo Europe to commercialize Nilemdo, a cholesterol lowering drug, across several European countries, extending its reach into treatments for high cardiovascular risk patients. This new commercial deal comes shortly after Organon’s stock gained about 21% over the past month. The move has drawn more attention to how its expanding cardiovascular portfolio might interact with upcoming earnings...

If you are wondering whether Somnigroup International at around US$94 is priced for perfection or still offers value, this breakdown will help you frame that question clearly. The share price comes with a 0.2% return over the last 7 days, 5.6% over 30 days, 5.9% year to date and 59.0% over the past year, with a 3 year return of 152.1% and 5 year return of 243.0% that many investors will want to put into context. Recent coverage has focused on Somnigroup International's position within its...

If you are wondering whether JPMorgan Chase at around US$312 per share is still good value or starting to look expensive, you are not alone. The stock has had a mixed run recently, with a 5.1% decline over the last 7 days and a 0.8% decline over the last 30 days, yet it shows a 23.0% return over 1 year and a very large 3 year and 5 year return of 148.4% and 165.2% respectively. Recent news around JPMorgan Chase has focused on its position as one of the largest global banks and its influence...

Recent share performance and business snapshot Tandem Diabetes Care (TNDM) has been under pressure recently, with the stock showing a 4.3% decline over the past day, 7.1% over the past week, and 10.1% over the past month, while gaining 36.3% over the past 3 months. The company reported revenue of US$1,007.001m and a net loss of US$203.366m, with annual revenue growth of 8.3% and annual net income growth that is very large. Its value score of 4 may interest investors who are comparing diabetes...

Recently, Exelon expanded its Customer Relief Fund with an additional US$10 million contribution, lifting total support to US$60 million over the past year to help households manage higher energy bills during cold weather. This stepped-up assistance, alongside Exelon’s advocacy for long-term affordability reforms, highlights how the utility is tying its financial resources to customer and community resilience. Next, we’ll examine how Exelon’s expanded customer relief efforts and...

What the recent move in Construction Partners means for investors Construction Partners (ROAD) has seen mixed share performance recently, with a 2% gain over the past day, a small decline over the past week, and a modest rise over the past month. This has kept investor attention focused on underlying fundamentals. See our latest analysis for Construction Partners. At a share price of US$114.42, Construction Partners has paired relatively modest recent share price moves with stronger longer...

If you are wondering whether AAR's current share price still offers value after a strong run, this article will walk through what the numbers say about where it stands today. AAR's share price closed at US$105.08, with returns of 8.3% over 7 days, 29.4% over 30 days, 24.4% year to date, 49.7% over 1 year, 118.0% over 3 years and 182.8% over 5 years. This naturally raises questions about what is already priced in. Recent company specific news and broader sector headlines have helped keep...

If you are wondering whether Teledyne Technologies at around US$581.72 is still reasonably priced or already looking expensive, you are not alone. The stock has recorded returns of 6.0% over the last 7 days, 15.7% over the last 30 days, 12.1% year to date, 22.8% over 1 year, 43.9% over 3 years and 49.5% over 5 years, which naturally raises questions about what is already reflected in the price. Recent coverage has focused on Teledyne’s role in high performance imaging and sensing...

Ameriprise Financial was recently recognized as the highest ranked diversified financial services firm on TIME’s 2026 list of “America’s Most Iconic Companies,” underscoring an independent assessment of its reputation, influence, and long-term contributions. This recognition highlights the strength of Ameriprise’s brand and its 132-year legacy, factors that can be important for clients and advisors when choosing a long-term financial partner. We’ll now explore how this TIME recognition,...

If you are wondering whether Rocket Lab's share price still makes sense after a big run, this article focuses squarely on what the current valuation is actually saying. The stock has been very strong recently, with a 13.5% return over the last 7 days, 78.5% over the last 30 days, 26.7% year to date and 301.2% over the past year. The 3 year return is very large at about 19x and the 5 year return stands at 817.1%. Recent news around Rocket Lab has highlighted its role in the commercial space...

If you are wondering whether Accenture's current share price really reflects its quality, you are not alone. Many investors are asking if the stock now offers value or still carries a premium. The shares last closed at US$286.21, with returns of 2.0% over 7 days, 4.6% over 30 days, 10.1% year to date, a 17.0% decline over 1 year, 7.7% over 3 years and 21.8% over 5 years. This gives a mixed picture of recent and longer term performance. Recent headlines around Accenture have focused on its...

If you are looking at United Rentals and wondering whether the current share price around US$921.24 still offers value, you are not alone. The stock price has had a mixed short term pattern, with a 1.9% decline over the last 7 days, a 16.2% gain over 30 days, a 9.0% return year to date and a 20.6% return over the past year. The 3 year return is very large at around 7x and the 5 year return is also very large. Recent news coverage around United Rentals has focused on its role as one of the...

Why First Horizon Is On Investors’ Radar Today First Horizon (FHN) is back in focus after a recent shift in its return profile, with the stock roughly flat year to date but showing a strong move over the past 3 months. See our latest analysis for First Horizon. While the share price has been roughly flat year to date, the 90 day share price return of 18.93% alongside a 1 year total shareholder return of 15.13% suggests momentum has recently picked up from a relatively subdued base. If this...

If you are wondering whether Adobe's current share price offers value or just more volatility, you are not alone. This article is built to help you frame that question clearly. Adobe's share price closed at US$296.12, with returns of an 11.3% decline over 7 days, a 16.5% decline over 30 days, an 11.2% decline year to date, a 31.1% decline over 1 year, a 16.9% decline over 3 years and a 37.3% decline over 5 years. This performance has sharpened the focus on what the stock might be worth...

Praxis Precision Medicines (PRAX) is drawing attention as it prepares two New Drug Applications for ulixacaltamide and relutrigine, both with FDA Breakthrough Therapy Designation, alongside the appointment of epilepsy expert Dr. Orrin Devinsky. See our latest analysis for Praxis Precision Medicines. The recent 7.21% 1 day and 20.07% 30 day share price returns, alongside a 68.02% 90 day share price return, suggest momentum is building around Praxis’s upcoming NDA filings and leadership...

In mid-January 2026, Intuit opened a new Intuit TurboTax flagship store in New York City’s SoHo neighborhood and completed a nationwide rollout of nearly 600 Expert Office locations and 20 TurboTax stores, all built around an AI-driven tax platform combined with human expertise. This physical expansion, which unites TurboTax and Credit Karma in a single in-person and digital experience, signals Intuit’s push to reshape how consumers access tax help and broader financial guidance during a...

Recent analyst updates on YETI Holdings (YETI), with several firms reaffirming Buy or Neutral views while lifting their valuation assumptions, have pushed the stock further onto investors’ radar despite a lack of new company specific headlines. See our latest analysis for YETI Holdings. The current share price of US$50.77 follows a 90 day share price return of 50.47% and a 1 year total shareholder return of 36.11%, suggesting momentum has been building over both shorter and longer...